Study of E-islet 01 for type 1 diabetes with severe low blood sugar
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a new treatment called E-islet 01, which may help people with type 1 diabetes who have very low natural insulin production and have had dangerous low blood sugar events. The goal is to see if it is safe and can reduce those episodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had type 1 diabetes for more than 5 years.
- Your body makes very little or no insulin (C-peptide level below 0.3 ng/mL).
- You have had a severe low blood sugar event in the past year, or you cannot feel when your blood sugar is low.
- You are willing to check your blood sugar regularly and follow the study plan.
- You do not have an active serious infection, cancer in the last 5 years, or have had recent organ or cell transplants.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether transplanting insulin-producing islet cells can improve blood sugar control and reduce severe low blood sugar in people with “brittle” type 1 diabetes. It’s meant for adults with long-standing insulin dependence and troublesome, hard-to-control hypoglycemia.
This trial looks at whether adding gastrin can improve outcomes after an islet cell transplant for people with type 1 diabetes. It may help some participants achieve better blood sugar control, but it also requires close follow-up and immune-suppressing medications to protect the new cells.
This trial tests whether transplanting insulin-producing “islet” cells can better control blood sugar in people who have already received a kidney transplant. It’s mainly for adults with type 1 diabetes whose body is no longer making enough insulin, while they are on kidney-transplant medicines.
This trial tests a new treatment made from pig pancreatic cells (called OPF-310) that are placed under the skin to help control blood sugar in people with type 1 diabetes. It is for those whose diabetes is difficult to manage and who have dangerous low blood sugar episodes.
This Phase 1/2 study tests whether CELZ-201 is safe and can help the body keep making some of its own insulin in people who were recently diagnosed with type 1 diabetes. You may be eligible if your diabetes started within the past year and your tests show you still have some insulin-making activity.
This study looks at how the body makes glucagon (a hormone that raises blood sugar) in children and teens with new type 1 diabetes. It aims to understand why some people may have dangerous low blood sugars, so doctors can better prevent them in the future.
Hear when a new Severe Hypoglycemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.